U.S. market Closed. Opens in 16 hours 51 minutes

IKT | Inhibikase Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue260.50K123.44K3.10M698.47K1.12M4.04M
Cost of Revenue177.40K6.72K11.36M893.80K2.55MN/A
Gross Profit83.10K116.72K-8.26M-195.33K-1.43M4.04M
Operating Expenses20.17M18.13M14.77M2.82M5.70M2.12M
Selling, General & Admin6.55M6.22M6.51M2.62M4.27M2.52M
Research & Development13.62M12.03M11.36M893.80K2.55M3.65M
Other Operating ExpensesN/A-123.44K-3.10M-698.47K-1.12MN/A
Operating Income-20.09M-18.13M-14.77M-2.82M-5.70M-2.12M
Other Expenses / Income1.06M74.45K-19.92K-29.40K-24.84K-30.33K
Before Tax Income-19.03M-18.05M-14.79M-2.85M-5.72M-2.15M
Income Tax Expenses2.00-148.91K19.92K29.40K24.84KN/A
Net Income-19.03M-17.91M-14.81M-2.88M-5.75M-2.15M
Interest ExpensesN/A74.45K19.92K29.40K24.84K30.33K
Basic Shares Outstanding5.33M4.20M3.03M1.68M1.72M1.34M
Diluted Shares Outstanding5.33M4.20M3.03M1.68M1.72M1.34M
EBITDA-19.91M-18.12M-14.77M-2.82M-5.70M-2.12M
EBITDA Margin-7,643.91%-14,680.72%-476.23%-403.52%-507.52%-52.52%
EBIT-19.03M-17.98M-14.77M-2.82M-5.70M-2.12M
EBIT Margin-7,304.75%-14,565.54%-476.23%-403.52%-507.52%-52.52%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙